CHEK2 and breast carcinoma: Although CHEK2 pathogenic variants are considered moderate-risk factors in breast cancer, the fact that it is so frequently found in breast cancer patients hypothesizes that there are other potentiating risk factors of the same molecular pathways or alternative pathways.